Clinical trials: Drug Eluting Stents
Coronary Artery Disease
Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation)
The primary objective of this study is to evaluate the safety and effectiveness of a direct stenting technique compared to conventional stenting with pre-dilatation strategy using the CoStar Paclitaxel-eluting coronary stent…
- Trial name
- DECIDE (NCT00440674)
- Testing
- CoStar Paclitaxel-eluting coronary stent system
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Conor Medsystems
Myocardial Infarction, Autonomic Dysfunction
The Usefulness of Assessing Heart Rate Variability in Patients With Acute Myocardial Infarction
Aims heart rate variability (HRV) assessment in patients with acute myocardial infarction who undergo primary percutaneous coronary intervention (PCI); measurement of HRV using a device approved for medical use in Europe…
- Trial name
- HeaRt-V-AMI (NCT05098977)
- Testing
- Heart rate variability measurement, Percutaneous coronary intervention
- Where
- Romania
- Volunteers
- 200 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Vertebrobasilar Insufficiency
Prospective Evaluation of Safety and Efficacy Vertebral Drug-eluting Stent System
The purpose of this study is to evaluate the safety and efficacy of Firehorus vertebral artery rapamycin-target-eluting stent system (hereinafter referred to as Firehorus) in treatment of symptomatic vertebral artery stenosis.
- Trial name
- PESS (NCT02328781)
- Testing
- Drug-eluting stent
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Zhongrong Miao
Coronary Artery Disease
OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation
Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by intravascular imaging (IVUS or OCT)…
- Trial name
- OPTIMIZE-APT (NCT05418556)
- Testing
- aspirin
- Where
- 33 sites in South Korea
- Volunteers
- 3,944 people
- Sponsor
- Asan Medical Center
Coronary Occlusion, Thrombosis (Stent Thrombosis)
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
This is a prospective, randomized, active-controlled, open label, parallel two-arm, multi-center, post-approval study descriptively comparing the XIENCE V EECSS to the CYPHER SELECT PLUS Sirolimus-Eluting Coronary Stent System…
- Conditions
- Coronary Occlusion, Thrombosis (Stent Thrombosis), Vascular Disease, Myocardial Ischemia
- Trial name
- NCT01178268
- Testing
- XIENCE V EECSS, CYPHER SELECT PLUS SECSS
- Where
- 2 sites in China
- Volunteers
- 546 people
- Sponsor
- Abbott Medical Devices
Emphysema
Exhale (R) Stent for Emphysema
Current treatment for emphysema is limited to measures that include inhaled oxygen, bronchodilators, anti-inflammatory drugs and pulmonary rehabilitation.
- Trial name
- NCT00207337
- Testing
- Exhale Drug-Eluting Stent
- Where
- 6 sites in Australia, Brazil and 1 more
- Volunteers
- 60 people
- Sponsor
- Broncus Technologies
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM (NCT00823212)
- Testing
- PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin
- Where
- 133 sites in United States, Australia and 15 more
- Volunteers
- 1,530 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW III Asia Registry Orsiro Stent System
Cliflical evaluation of th' Orsiro LESS 10 diabetic subjects requiring coronary revasculariza t ion with Drug Eluting Stefl ts (DES) .880 subjects will be enrolled in this registry.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01941290
- Where
- 19 sites in China, India and 3 more
- Volunteers
- 387 people
- Sponsor
- BIOTRONIK Asia Pacific Pte Ltd
Coronary Artery Disease
Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent
The RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a "real world, all comers" study.
- Trial name
- RESOLUTE-AC (NCT00617084)
- Testing
- Medtronic Endeavor Resolute, Abbott Xience V
- Where
- Switzerland
- Volunteers
- 2,292 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease, Drug-eluting Stent
A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease (PROPEL)
This is a prospective, multicenter, historical controlled study. The present clinical study will measure non-inferiority of 12 month TLF rate compared to historical control.The selected historical control is the Xience V arm from…
- Trial name
- NCT01808391
- Where
- Japan
- Volunteers
- 1,204 people, healthy volunteers welcome
- Sponsor
- Associations for Establishment of Evidence in Interventions
Drug-eluting Stent, Coronary Artery Disease
Genoss DES in Patients With a High Risk of Ischemic Events (GENTLE Registry)
This is a prospective cohort study to evaluate the long-term effect and safety of Genoss drug-eluting stents (DES) in patients with coronary artery disease with high ischemic features.
- Trial name
- NCT05448625
- Testing
- Genoss DES
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Multi Vessel Coronary Artery Disease, Percutaneous Coronary Intervention
Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD
This study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with…
- Trial name
- DCBMultivessel (NCT07539324)
- Testing
- GENOSS® DCB (Paclitaxel-coated PTCA balloon catheter), Contemporary Drug-Eluting Stents (DES)
- Where
- South Korea
- Volunteers
- 892 people
- Sponsor
- Genoss Co., Ltd.
Coronary Artery Disease
Comparison of Paclitaxel-Coated Balloons Against Drug-Eluting Bioresorbable Scaffolds for Elective PCI Using OCT
This prospective randomized clinical trial aims to compare two different "metal-free" strategies for elective percutaneous coronary revascularization: the FFR-guided DCB-only PCI (drug-coated balloon: SeQuent Please™, B Braun…
- Trial name
- OCTOPUS-3 (NCT02607241)
- Testing
- OCT-guided BRS implantation, FFR-guided DCB-only PCI
- Where
- Germany
- Volunteers
- 59 people
- Sponsor
- University of Jena
Hypertension, Coronary Artery Disease
Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was…
- Trial name
- NCT00139386
- Testing
- Candesartan
- Where
- Japan
- Volunteers
- 1,119 people
- Sponsor
- Kumamoto University
Coronary Artery Disease
Japan Unprotected Left Main Coronary Artery Disease Percutaneous Coronary Intervention (PCI) Strategy On New Generation Stents
The main purpose of this study is to observe the incidence of major adverse cardiac and cerebrovascular events (MACCE), target vessel failure (TVF), target vessel revascularization (TVR) and stent thrombosis out to 5 years after…
- Trial name
- J-LESSON (NCT01256723)
- Where
- Japan
- Volunteers
- 441 people
- Sponsor
- Associations for Establishment of Evidence in Interventions
Coronary Artery Disease
PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
The primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the XIENCE or Promus durable polymer coronary…
- Trial name
- NCT03168776
- Testing
- BuMA Supreme DES, Xience or Promus DES
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 1,629 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Coronary Disease
CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation
This study is designed to evaluate the performance and safety of a new catheter system.
- Trial name
- NCT00422435
- Testing
- CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
- Where
- Belgium
- Volunteers
- 107 people
- Sponsor
- Conor Medsystems
Coronary Artery Disease, Coronary Disease
Evaluation of Effectiveness and Safety of XIENCE Sierra in Routine Clinical Practice
The objective of this study is to evaluate effectiveness and safety of Xience Sierra stent in the "real world" daily practice as compared with other drug-eluting stents.
- Trial name
- IRIS Sierra (NCT03967158)
- Testing
- Xience Sierra stent
- Where
- 10 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease, Diabetes Mellitus
Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients
This study is a prospective, randomized controlled, single blind, two-arm, multicenter clinical evaluation. Diabetic patients (n=112) with de novo coronary artery disease will be randomized to one of the 2 treatment arms: 1)…
- Trial name
- RESERVOIR (NCT01710748)
- Testing
- Polymer-Based Everolimus-Eluting Stent, Polymer-Free Amphilimus-Eluting Stent
- Where
- 4 sites in Spain
- Volunteers
- 112 people
- Sponsor
- Spanish Society of Cardiology
Coronary Artery Disease
BIOTRONIK Orsiro Pre-Marketing Registration
The clinical investigation is a non-inferiority, multicenter, blinding evaluation, randomized, parallel controlled clinical study enrolling up to 440 subjects.
- Trial name
- BIOFLOW-VI (NCT02870985)
- Testing
- Coronary Stent
- Where
- China
- Volunteers
- 440 people
- Sponsor
- Biotronik (Beijing) Medical Device Ltd.